Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034

被引:191
|
作者
Tong, Xiao [1 ]
Chase, Robert [1 ]
Skelton, Angela [1 ]
Chen, Tong [1 ]
Wright-Minogue, Jackie [1 ]
Malcolm, Bruce A. [1 ]
机构
[1] Schering Plough Res Inst, Dept Virol, Kenilworth, NJ 07033 USA
关键词
hepatitis C virus; protease; inhibitor; resistance; antiviral;
D O I
10.1016/j.antiviral.2005.12.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
HCV NS3 protease variants resistant to the protease inhibitor SCH 503034 were selected. Three mutations, T54A, V170A and A 156S mutations conferred low to moderate levels of resistance (< 20-fold). Longer exposure (> 10 passages) or selection with higher levels of compound led to the selection of a more resistant variant, A156T (> 100-fold). [Lin, C., Lin, K., Luong, Y.P., Rao, B.G., Wei, Y.Y., Brennan, D.L., Fulghum, J.R., Hsiao, H.M., Ma, S., Maxwell, J.P., Cottrell, K.M., Perni, R.B., Gates, C.A., Kwong, A.D., 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279(17), 17508-17514; Lu, L., Pilot-Matias, T.J., Stewart, K.D., Randolph, J.T., Pithawalla, R., He, W., Huang, P.P., Klein, L.L., Mo, H., Molla, A., 2004. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48(6), 2260-2266.] Combination with IFN-alpha drastically reduced the number of emergent colonies. Resistant colonies showed no change in sensitivity to IFN-alpha. Although the A156T mutation conferred the highest level of resistance to SCH503034, it significantly reduced the colony formation efficiency (CFE) of the mutant replicon RNA, and rendered replicon cells less fit than those bearing wild-type replicons. Replicon cells bearing mutation A156S were less fit than wild-type in co-culture growth competition assays but showed no impact on CFE. The V170A mutation, on the other hand, did not affect replicon fitness in either assay, which was consistent with its emergence as the dominant mutant after 12 months of continuous selection. The reduced fitness of the most resistant variant suggests that it may be rare in naive patients and that development of high-level resistance may be slow. Combination therapy with IFN-alpha should also greatly reduce the potential emergence of resistance. (c) 2006 Elsevier B.V. All rights reserved.
引用
下载
收藏
页码:28 / 38
页数:11
相关论文
共 50 条
  • [21] SCH 503034, a mechanism-based inhibitor of hepatitis C virus (HCV) NS3 protease suppresses polyprotein maturation and enhances the antiviral activity of interferona-211 (INF)
    Malcolm, BA
    Arassappan, A
    Bennett, F
    Bogen, S
    Chase, R
    Chen, K
    Chen, T
    Ingravallo, P
    Jao, E
    Kong, S
    Lahser, F
    Liu, R
    Liu, YT
    Lovey, R
    McCormick, J
    Njoroge, GF
    Saksana, A
    Skelton, A
    Tong, X
    Venkatraman, S
    Wright-Minogue, J
    Xia, E
    Girijavallabhan, V
    HEPATOLOGY, 2005, 42 (04) : 535A - 536A
  • [22] CHARACTERIZATION OF VIRAL RESISTANCE MUTATIONS IN GENOTYPE 1 HCV PATIENTS RECEIVING COMBINATION THERAPY WITH A PROTEASE INHIBITOR AND A POLYMERASE INHIBITOR WITH OR WITHOUT RIBAVIRIN
    Mo, H.
    Harris, J.
    Bae, A.
    Hebner, C.
    Wong, K.
    Delaney, W.
    Oldach, D.
    Miller, M. D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S484 - S484
  • [23] Structural Analysis of Darunavir Analogs Against Primary Resistance Mutations in HIV Protease
    Lockbaum, Gordon Joseph
    Leidner, Florian
    Rusere, Linah
    Nalivaika, Ellen
    Ali, Akbar
    Kurt-Yilmaz, Nese
    Schiffer, Celia
    FASEB JOURNAL, 2018, 32 (01):
  • [24] Discovery of SCH446211 (SCH6): A new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication
    Bogen, SL
    Arasappan, A
    Bennett, F
    Chen, K
    Jao, E
    Liu, YT
    Lovey, RG
    Venkatraman, S
    Pan, WD
    Parekh, T
    Pike, RE
    Ruan, S
    Liu, R
    Baroudy, B
    Agrawal, S
    Chase, R
    Ingravallo, P
    Pichardo, J
    Prongay, A
    Brisson, JM
    Hsieh, TY
    Cheng, KC
    Kemp, SJ
    Levy, OE
    Lim-Wilby, M
    Tamura, SY
    Saksena, AK
    Girijavallabhan, V
    Njoroge, FG
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (09) : 2750 - 2757
  • [25] Combination therapy with the HCV protease inhibitor, SCH 503034, plus peg-intron in hepatitis C genotype-1 peg-intron non-responders: Phase IB results
    Zeuzem, S
    Sarrazin, C
    Wagner, F
    Rouzier, R
    Forestier, N
    Gupta, S
    Hussain, M
    Shah, A
    Cutler, DL
    Zhang, J
    HEPATOLOGY, 2005, 42 (04) : 276A - 277A
  • [26] Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients
    Trimoulet, P.
    Belzunce, C.
    Faure, M.
    Wittkop, L.
    Reigadas, S.
    Dupon, M.
    Ragnaud, J-M
    Fleury, H.
    Neau, D.
    HIV MEDICINE, 2011, 12 (08) : 506 - 509
  • [27] HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
    Rhee, Soo-Yon
    Taylor, Jonathan
    Fessel, W. Jeffrey
    Kaufman, David
    Towner, William
    Troia, Paolo
    Ruane, Peter
    Hellinger, James
    Shirvani, Vivian
    Zolopa, Andrew
    Shafer, Robert W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (10) : 4253 - 4261
  • [28] Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
    Winters, Mark A.
    Lloyd, Robert M., Jr.
    Shafer, Robert W.
    Kozal, Michael J.
    Miller, Michael D.
    Holodniy, Mark
    PLOS ONE, 2012, 7 (07):
  • [29] Protease Inhibitor Resistance Mutations in Untreated Brazilian Patients Infected with HCV: Novel Insights about Targeted Genotyping Approaches
    de Carvalho, Isabel M. V. G.
    Alves, Rafael
    Vasconcelos-Medeiros de Souza, Polyana A.
    da Silva, Edvaldo F.
    Mazo, Daniel
    Carrilho, Flair J.
    Queiroz, Artur T. L.
    Pessoa, Mario G.
    JOURNAL OF MEDICAL VIROLOGY, 2014, 86 (10) : 1714 - 1721
  • [30] Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro
    Lu, Liangjun
    Dekhtyar, Tatyana
    Masse, Sherie
    Pithawalla, Ron
    Krishnan, Preethi
    He, Wenping
    Ng, Teresa
    Koev, Gennadiy
    Stewart, Kent
    Larson, Dan
    Bosse, Todd
    Wagner, Rolf
    Pilot-Matias, Tami
    Mo, Hongmei
    Molla, Akhteruzurnman
    ANTIVIRAL RESEARCH, 2007, 76 (01) : 93 - 97